A study published in The American Journal of Drug and Alcohol found that long-term cannabis users experience interfered with sleep and memory. The findings

A review published in the American Journal of Obstetrics and Gynecology found a slight increase in the risk of Attention Deficit Hyperactivity Disorder (AD

A new poll shows that 21% of people aged 50 years and up used cannabis in the last year, with 12% taking the substance at least once per month.

A study published in the Journal of Medical Toxicology compared incidents of adverse Delta-8 effects in states with and without legal cannabis. States with

Grow rooms are a prominent example of the potential and the challenges of indoor agriculture.

A big part of the growth cycle of the cannabis plant is deeply rooted in the ability of the plant to absorb and rid itself of water vapor, so we now add a D to HVAC for dehumidification.

Fruit Slabs start as a cannabis-infused fruit blend with no added sugar that is then dried into a bite-sized square. 

In this episode the topic is 3D printed blister tool prototyping and how it can be used to improve cannabis packaging.

In this episode, we talk with Ron Basak-Smith, Co-Founder & CEO, and James Eichner, Co-Founder & CSO, of Sana Packaging — a sustainable packaging brand that designs and develops differentiated, sustainable and compliant cannabis packaging solutions for a circular economy by using 100% plant-based hemp plastic, 100% reclaimed ocean plastic and other sustainable materials.

Despite being surrounded in controversy, the U.S. cannabis industry is experiencing rapid growth. Experts estimate legal cannabis will grow from $7.3 billion to $24.5 billion between 2016 and 2020. Currently, 65 percent of cannabis sales stem from medical marijuana.

According to a report from Zion Market Research, the global cannabis edibles market was valued at approximately USD 2,376 million in 2018 and is expected to generate around USD 11,564 million by 2025, at a CAGR of around 25.4% between 2019 and 2025.

In this episode with Chirag Sheth, Global Business Unit Manager at Videojet, we discuss coding and marking options for cannabis packaging.

The two principal purposes of packaging are to protect the product it carries and the consumer who buys it, and to market that product to purchasers, both directly and indirectly.

Learn more about how these companies are leading the charge when it comes to developing and offering innovative and sustainable cannabis packaging solutions.

With April 20 approaching, we look at how cannabis producers can partner with local printers to create high-quality packaging that adheres to local laws and regulations while also establishing brand identity and increasing brand recognition.

Washington, D.C. – The House Appropriations Committee advanced the FY 2023 Financial Services and General Government appropriations bill which included language that would prevent the FCC from taking administrative action against broadcasters that accept cannabis advertisements consistent with the law of the state or jurisdiction in which the station is licensed.

Washington, D.C. – The U.S. House of Representatives today passed the FY 2023 Financial Services and General Government appropriations bill, which included language that would prevent the FCC from taking administrative action against broadcasters that accept cannabis advertisements consistent with the law of the state or jurisdiction in which the station is licensed.

WASHINGTON, D.C. -- In response to Sen. Ben Ray Luján’s (D-NM) introduction of the Secure and Fair Enforcement (SAFE) Advertising Act, which would clarify that local radio and television broadcasters may air cannabis advertisements in states where it is legal without the threat of administrative action from the FCC, the following statement can be attributed to NAB President and CEO Curtis LeGeyt:

Priority Software Ltd.,a global provider of business management solutions, has announced that GL Brands, Inc., a multi-national consumer packaged goods company serving the global hemp and CBD markets, has implemented Priority Cannabis ERP, a comprehensive seed-to-sale ERP software solution, to effectively manage the entire plant lifecycle.

Fen Health Ltd and Zulize Ltd have announced a transaction that will see both companies merge to form and launch, Fen Group Ltd.

Buenos Aires hosts South America’s largest cannabis fair

Count on a varied, immersive scene Saturday when Tucson Doobie presents Halloweed at Generation Cool…

A study published in JAMA Pediatrics found cohesive links between prenatal cannabis use and poor thinking skills, lack of impulse control, issues with planning and paying attention and an increase in aggressive behavior among preschool-aged children…

Vice President Kamala Harris announced last week her intention, if elected president, to "legalize marijuana at the federal level."…

The Washington State Liquor and Cannabis Board recently released sales and tax data from fiscal 2024 — July 1, 2023, through June 30, 2024…

There is a lot more to weed than just getting high…

Así lo asegura Jaime Arteaga, director del Observatorio Colombiano de la Industria del Cannabis. 

POLICE seized nearly 1000 cannabis plants in two simultaneous raids at industrial premises at Brookvale and Cromer this morning with six men taken into custody over the $3m haul.

Mike Tyson’s new line of boxing glove-shaped cannabis gummies launched exclusively in Colorado this week, and the reason why might come as a surprise.

As public support for marijuana decriminalization grows, new research is shedding light on the drug’s impact on sleep and memory.

“More than sixty cannabis plants in various stages of growth” were “seized and subsequently destroyed,” the police confirmed. A police spokesperson said, “Shortly before 6:00 p.m. on Tuesday, September 3, 2024, police officers were on mobile patrol when they had occasion to attend a property in the area of Mission Lane, Pembroke. “A check of the […]

Here’s how cannabis use became prohibited—and the science of its biological, psychological, and social effects.

Yasmin L. Hurd
Oct 16, 2019; 39:8250-8258
Symposium and Mini-Symposium

During adolescence, cannabis experimentation is common, and its association with interindividual variations in brain maturation well studied. Cellular and molecular underpinnings of these system-level relationships are, however, unclear. We thus conducted a three-step study. First, we exposed adolescent male mice to -9-tetrahydrocannabinol (THC) or a synthetic cannabinoid WIN 55,212-2 (WIN) and assessed differentially expressed genes (DEGs), spine numbers, and dendritic complexity in their frontal cortex. Second, in human (male) adolescents, we examined group differences in cortical thickness in 34 brain regions, using magnetic resonance imaging, between those who experimented with cannabis before age 16 (n = 140) and those who did not (n = 327). Finally, we correlated spatially these group differences with gene expression of human homologs of mouse-identified DEGs. The spatial expression of 13 THC-related human homologs of DEGs correlated with cannabis-related variations in cortical thickness, and virtual histology revealed coexpression patterns of these 13 genes with cell-specific markers of astrocytes, microglia, and a type of pyramidal cells enriched in dendrite-regulating genes. Similarly, the spatial expression of 18 WIN-related human homologs of DEGs correlated with group differences in cortical thickness and showed coexpression patterns with the same three cell types. Gene ontology analysis indicated that 37 THC-related human homologs are enriched in neuron projection development, while 33 WIN-related homologs are enriched in processes associated with learning and memory. In mice, we observed spine loss and lower dendritic complexity in pyramidal cells of THC-exposed animals (vs controls). Experimentation with cannabis during adolescence may influence cortical thickness by impacting glutamatergic synapses and dendritic arborization.

As Delaware readies for the upcoming launch of the state’s legal adult-use cannabis industry, state lawmakers approved legislation, proposed by State Treasurer Colleen Davis, providing protections for banks and other financial institutions that serve licensed marijuana businesses. Although marijuana remains illegal at the federal level, Delaware has joined many other states in legalizing it for […]

Eco Equity is one of only a few Europe-based investors in medicinal cannabis from Africa and the Caribbean, an area in which the UK is missing an opportunity, according to CEO Jon-Paul Doran.

Italy's flourishing "cannabis light" industry is at risk, with Prime Minister Giorgia Meloni pushes a bill through parliament to deflower a crop that is legal across much of Europe. Her conservative coalition wants to ban the sale of hemp flower products, but those in the trade say it's economic suicide. - REUTERS

Family physicians are fielding questions about cannabis --particularly for the use of cannabis for treatment of pain. Like about every substance ingested to treat medical conditions, cannabis has risks and benefits. But regarding evidence-based practice and practice-based recommendations for patients about cannabis use, the cart is in front of the horse. Cannabis use is still illegal at a federal level and a Schedule 1 drug, but most states have challenged federal law by decriminalizing or legalizing cannabis for a variety of uses. Research is difficult due to this federal status as a Schedule 1 drug since federal funding is not readily available to support research. As a result, physicians have little to no guidance about the clinical usefulness of the product. This article explores what we know and what we are learning about cannabis, and the authors provide clinical guidance for patient care based on this evidence.

Chronic pain conditions affect nearly 20% of the population in the United States. Current medical interventions, such as opioid drugs, are effective at relieving pain but are accompanied by many undesirable side effects. This is one reason increased numbers of chronic pain patients have been turning to Cannabis for pain management. Cannabis contains many bioactive chemical compounds; however, current research looking into lesser-studied minor cannabinoids in Cannabis lacks uniformity between experimental groups and/or excludes female mice from investigation. This makes it challenging to draw conclusions between experiments done with different minor cannabinoid compounds between laboratories or parse out potential sex differences that could be present. We chose five minor cannabinoids found in lower quantities within Cannabis: cannabinol (CBN), cannabidivarin (CBDV), cannabigerol (CBG), 8-tetrahydrocannabinol (8-THC), and 9-tetrahydrocannabivarin (THCV). These compounds were then tested for their cannabimimetic and pain-relieving behaviors in a cannabinoid tetrad assay and a chemotherapy-induced peripheral neuropathy (CIPN) pain model in male and female CD-1 mice. We found that the minor cannabinoids we tested differed in the cannabimimetic behaviors evoked, as well as the extent. We found that CBN, CBG, and high-dose 8-THC evoked some tetrad behaviors in both sexes, while THCV and low-dose 8-THC exhibited cannabimimetic tetrad behaviors only in females. Only CBN efficaciously relieved CIPN pain, which contrasts with reports from other researchers. Together these findings provide further clarity to the pharmacology of minor cannabinoids and suggest further investigation into their mechanism and therapeutic potential.

The consumption of ⁹-tetrahydrocannabinol (THC)- or cannabis-containing edibles has increased in recent years; however, the behavioral and neural circuit effects of such consumption remain unknown, especially in the context of ingestion of higher doses resulting in cannabis intoxication. We examined the neural and behavioral effects of acute high-dose edible cannabis consumption (AHDECC). Sprague-Dawley rats (six males, seven females) were implanted with electrodes in the prefrontal cortex (PFC), dorsal hippocampus (dHipp), cingulate cortex (Cg), and nucleus accumbens (NAc). Rats were provided access to a mixture of Nutella (6 g/kg) and THC-containing cannabis oil (20 mg/kg) for 10 minutes, during which they voluntarily consumed all of the provided Nutella and THC mixture. Cannabis tetrad and neural oscillations were examined 2, 4, 8, and 24 hours after exposure. In another cohort (16 males, 15 females), we examined the effects of AHDECC on learning and prepulse inhibition and serum and brain THC and 11-hydroxy-THC concentrations. AHDECC resulted in higher brain and serum THC and 11-hydroxy-THC levels in female rats over 24 hours. AHDECC also produced: 1) Cg, dHipp, and NAc gamma power suppression, with the suppression being greater in female rats, in a time-dependent manner; 2) hypolocomotion, hypothermia, and antinociception in a time-dependent manner; and 3) learning and prepulse inhibition impairments. Additionally, most neural activity and behavior changes appear 2 hours after ingestion, suggesting that interventions around this time might be effective in reversing/reducing the effects of AHDECC.

The National Center for Complementary and Integrative Health (NCCIH), which is part of the US National Institutes of Health (NIH), has a broad interest in studying the biologic activities of natural products, especially those for which compelling evidence from preclinical research suggests biologic activities that may be beneficial to health or have a potential role in disease treatment, as well as products used extensively by the American public. As of 2023, use of cannabis for medical purposes is legal in 38 states and Washington, D.C. Such use continues to climb generally without sufficient knowledge regarding risks and benefits. In keeping with NCCIH’s natural product research priorities and recognizing this gap in knowledge, NCCIH formally launched a research program in 2019 to expand research on the possible benefits for pain management of certain substances found in cannabis: minor cannabinoids and terpenes. This Viewpoint provides additional details and the rationale for this research priority at NCCIH. In addition, NCCIH’s efforts and initiatives to facilitate and coordinate an NIH research agenda focused on cannabis and cannabinoid research are described.

Cannabis and its products have been used for centuries for both medicinal and recreational purposes. The recent widespread legalization of cannabis has vastly expanded its use in the United States across all demographics except for adolescents. Meanwhile, decades of research have advanced our knowledge of cannabis pharmacology and particularly of the endocannabinoid system with which the components of cannabis interact. This research has revealed multiple targets and approaches for manipulating the system for therapeutic use and to ameliorate cannabis toxicity or cannabis use disorder. Research has also led to new questions that underscore the potential risks of its widespread use, particularly the enduring consequences of exposure during critical windows of brain development or for consumption of large daily doses of cannabis with high content ⁹-tetrahydrocannabinol. This article highlights current neuroscience research on cannabis that has shed light on therapeutic opportunities and potential adverse consequences of misuse and points to gaps in knowledge that can guide future research.

Today’s cannabis plant is highly cultivated and incredibly potent. Treating it like a commodity, and not a testable, regulated medicine, is hurting people

Cannabis containing 10% or more of the psychoactive compound THC (Delta-9-tetrahydrocannabinol), can alter the DNA (!--ref1--). A recent study published

Discover how Cannabinol (CBN) found in cannabis can improve sleep, based on groundbreaking research from the University of Sydney.